摘要
目的观察分析利拉鲁肽对2型糖尿病患者糖化血红蛋白、缺铁修饰白蛋白表达及预后的影响。方法随机抽取我院2型糖尿病患者88例,根据随机数表法分组,对照组与观察组各44例,对照组患者采用二甲双胍(晚饭后口服,初始剂量500mg/d,1次/日,根据血糖控制水平以500mg为单位逐周加量),观察组患者在使用二甲双胍治疗的基础上联合利拉鲁肽(皮下注射,初始剂量0.6mg/d,1次/日,根据血糖控制水平以0.6mg为单位逐周加量,最多1.8mg/次)治疗,两组患者均连续治疗12周,观察两组患者的血糖、体质量指数、糖化血红蛋白、缺铁修饰白蛋白表达情况,并统计不良反应及预后情况。结果治疗前,两组患者的HBA1c、缺铁修饰白蛋白(IMA)、FPG、2hPG水平及BMI比较差异无统计学意义(P>0.05)。两组患者治疗后4周、8周、12周,HBA1c、IMA、FPG、2hPG水平及BMI均呈现出下降趋势,差异有统计学意义(P<0.05)。治疗后8周、12周,观察组患者的HBA1c水平[(6.98±0.87)%、(6.71±0.85)%]均明显低于对照组患者[(7.64±0.92)%、(7.45±0.90)%],差异有统计学意义(P<0.05)。治疗后4周、8周、12周观察组患者的IMA、FPG、2hPG水平及BMI均明显低于对照组患者,差异有统计学意义(P<0.05)。治疗过程中观察组患者不良反应总发生率为11.36%,对照组发生率为9.09%,无明显差异(P>0.05),无严重低血糖发生,对症处理后均好转,安全性高。结论拉利鲁肽可控制2型糖尿病患者缺铁修饰白蛋白表达,降低HBA1c水平、FPG水平、2hPG水平、BMI,有利于维持患者血糖平稳,提高治疗效果,安全性高。
Objective To observe the effect of liraglutide on the expression of glycated hemoglobin,iron-deficient modified albumin and prognosis in type 2 diabetic patients.Methods Eighty-eight cases of type 2 diabetic patients were randomly selected.According to random number table method group,the control group and the observation group of 44 cases.Patients in the control group were treated with metformin（orally after dinner,initial dose of 500 mg/d,once daily,and daily dosage of 500 mg according to the level of glycemic control）,when patients in the observation group were treated with metformin combined with liraglutide（subcutaneous injection,initial dose 0.6 mg/d,once daily,0.6 mg weekly based on blood glucose level control,up to 1.8 mg once）on the basis of metformin treatment.Two groups of patients were treated for 12 weeks,and the blood glucose,body mass index,glycosylated hemoglobin,iron-deficient modified albumin expression in two groups was observed,and was observed statistics and adverse reactions and prognosis.Results Before treatment,there was no significant difference in HBA1c,IMA,FPG,2 hPG and BMI between the two groups（P0.05）.The levels of HBA1c,IMA,FPG,2 hPG and BMI showed a decreasing trend at 4 weeks,8 weeks and 12 weeks after treatment in both groups（P0.05）.The levels of HBA1c in the 12-week observation group（6.98±0.87）%,（6.71±0.85）% after 8 weeks of treatment were significantly lower than those in the control group（7.64±0.92）%,（7.45±0.90）%,and the difference was statistically significant（P0.05）.The levels of IMA,FPG,2 hPG and BMI in the observation group at 4,8 and 12 weeks after treatment were significantly lower than those in the control group（P0.05）.The total incidence of adverse reactions in the observation group was 11.36%,while the incidence in the control group was 9.09%.There were no statistical significantly differences（P0.05）,no severe hypoglycemia occurred,and it was all improved after symptomatic treatment,and the safety was high.Conclusion Lira
作者
王之秀
冯庆
曹辉彩
陈翼霖
Wang Zhixiu;Feng Qing;Cao Huicai;Chen Yilin(Department of Clinical Laboratory, the First Center Hospital of Baoding City. Baoding 071000,Hebei, China;Department of Medical Examination Center, the Affiliated Hospital of Heibei University. Baoding 071000,Hebei, China.)
出处
《贵州医药》
CAS
2018年第5期529-532,共4页
Guizhou Medical Journal
